COMMUNIQUÉS West-GlobeNewswire

Public Hearings on Protecting and Improving Local Hospitals: Community members invited to give input
03/06/2024
TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- In response to more than 1,200 closures of emergency departments and other local hospital services over the last year, the Ontario Health Coalition (OHC) is holding public [...]
Late-breaking results from PALOMA-2 study of subcutaneous RYBREVANT®▼ (amivantamab) in combination with lazertinib show clinically meaningful antitumour response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer
03/06/2024
Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data 1 BEERSE, BELGIUM, June 03, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag [...]
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
03/06/2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length [...]
L’anticorps MCLA-129 produit par Merus ou la promesse d’une monothérapie efficace dans le traitement du CPNPC présentant une mutation de l’exon 14 du gène MET - une présentation sous forme de poster est prévue lors du congrès annuel 2024 de l’ASCO®
03/06/2024
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 03 juin 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après « Merus, la Société, nous, ou notre », une société spécialisée dans l’oncologie au stade [...]
NADP Push for Greater Access to Dental Benefits Gaining Traction in Congress
03/06/2024
CBO estimates Independent Purchase of Dental Plans Would Reduce Deficit DALLAS, June 03, 2024 (GLOBE NEWSWIRE) -- After the National Association of Dental Plans (NADP) advocated for the passage of the Increasing Access [...]
Conor McGregor and Virat Kohli Collaborate to Launch TIDL's Innovative Pain Relief Products in India
03/06/2024
TIDL’s Game-Changing Products Now Rolling Out to 40,000 Stores Across India LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- TIDL, the fastest-growing pain relief brand in the United States , is thrilled to announce its [...]
Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility
03/06/2024
Company reaffirms commitment to maintaining appropriate standards of animal welfare WEST LAFAYETTE, Ind., June 03, 2024 (GLOBE NEWSWIRE) -- Inotiv Inc. – Inotiv Inc. (“Inotiv” or the “Company”) (Nasdaq: NOTV), a leading [...]
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
03/06/2024
HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) -- 7 Hills Pharma Inc. (“7 Hills” or “7HP”), a clinical-stage pharma company leveraging a novel mechanism of action to safely enhance the effectiveness of cancer immunotherapies, [...]
Oswego Health Partners with Wellthy to Deliver Comprehensive Caregiving Support to Employees and their Families
03/06/2024
Oswego Health becomes the largest healthcare employer in Central New York to partner with Wellthy to support employee caregivers New York, NY, June 03, 2024 (GLOBE NEWSWIRE) -- Oswego Health – the Central New York [...]
Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
03/06/2024
HINGHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company’s common [...]
ALK launches new growth strategy and 2028 financial ambitions
03/06/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the Board of Directors has adopted a new corporate strategy (Allergy + ) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s leadership in [...]
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
03/06/2024
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine New PATHFNDR-1 [...]
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
03/06/2024
Coverage policy determination initiated with 5 Medicare MACs for HeartFlow's AI-QCT revolutionizing cardiovascular care for patients MOUNTAIN VIEW, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in [...]
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
03/06/2024
100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg) CAH Participants Achieved More Than a 90% Reduction of A4 and 97% Reduction of [...]
CenTrak Announces Partnership with The Leapfrog Group
03/06/2024
Partner Advisory Committee Membership Demonstrates Enhanced Commitment to Healthcare Safety NEWTOWN, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- CenTrak , the leader in real-time location technology solutions, announces its [...]
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
03/06/2024
Saint-Herblain (France), June 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vaccine candidate, [...]
Valneva annonce la publication de deux essais de Phase 2 sur la maladie de Lyme dans le Lancet Infectious Diseases
03/06/2024
Saint-Herblain (France), 3 juin 2024 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que les résultats de deux essais cliniques de Phase 2 sur le candidat [...]
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
03/06/2024
Merck KGaA, Darmstadt, Germany, will leverage Biolojic Design’s AI capabilities to create potential best-in-class multi-specific antibodies that uniquely modulate biology Collaboration designed to deliver immunology and [...]
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
03/06/2024
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on pharmacokinetics of morning and [...]

Pages